著者 Maksym Misichenko · Yahoo Finance ·
AIエージェントがこのニュースについて考えること
The panelists agree that Eli Lilly's Verve-102 and retatrutide programs show early promise but face significant hurdles, including manufacturing challenges, regulatory risks, and payer acceptance. The market's high valuation already prices in perfection, making it vulnerable to any setbacks.
リスク: Regulatory tail risk and payer acceptance for one-time edits
機会: Potential paradigm shift from chronic GLP-1 injections to one-and-done genetic medicine
本分析は StockScreener パイプラインで生成されます — 4 つの主要な LLM（Claude、GPT、Gemini、Grok）が同じプロンプトを受け取り、組み込みの幻覚防止ガードが備わっています。 方法論を読む →
Eli Lilly and Company (NYSE:LLY) は、
12 Most Profitable Stocks to Invest In のひとつです。
2026年5月25日、Eli Lilly and Company (NYSE:LLY) は、肝臓でPCSK9遺伝子を永続的にオフにし、単一の輸血後に低密度リポタンパク質コレステロールを下げるように設計された、in vivoベース編集薬Verve-102 の Phase 1b Heart-2 試験の肯定的な結果を発表しました。 35人の参加者の暫定解析において、Verve-102 の一回投与は、0.3 mg/kg の投与量から 1.0 mg/kg の投与量までの範囲で、51% から 88% までの用量依存性の平均 PCSK9 減少をもたらしました。 対応する平均 LDL-C 減少は、9%、44%、45%、33%、51%、および 62% で、治療後最大18ヶ月までの持続性が観察されました。
2026年5月21日、Wolfe Research は、Eli Lilly and Company (NYSE:LLY) が、80 週間で最大 26.1%、104 週間で 30% を超える体重減少を、より BMI の高い参加者において示している retatrutide の Phase 3 結果を報告したと述べました。「クラスをリードする」体重減少です。 Wolfe は、このデータはまた、主要な心血管 代謝リスクマーカーの広範な改善を示しており、Eli Lilly の GLP-1 分野のリーダーシップと肥満治療プロファイルをさらに強化していると述べました。 Wolfe は、Outperform レーティングと $1,350 の株価目標を維持しました。
一方、RBC Capital は、Eli Lilly and Company (NYSE:LLY) に対する Outperform レーティングと $1,250 の株価目標を維持しました。 RBC は、retatrutide Phase 3 治験はクリーンな勝利であり、クリーンな安全性プロファイルとすべての投与量にわたる最高の有効性を示していると述べました。 RBC は、2027 年に retatrutide を発売し、2030 年の売上高を 49 億ドル、2034 年の売上高を 110 億ドルとモデル化しており、成功確率は 70% であると述べました。
Eli Lilly and Company (NYSE:LLY) は、国際的に人間の医薬品を探索、開発、製造、販売しています。
LL Y の投資としての潜在性を認識していますが、特定の AI 株の方がより大きな上昇ポテンシャルがあり、より少ない下落リスクを伴うと考えています。 トランプ時代の関税とオンショアリングの傾向からも大幅な恩恵を受ける、非常に割安な AI 株を探している場合は、当社の best short-term AI stock の無料レポートをご覧ください。
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
4つの主要AIモデルがこの記事を議論
"Early-stage gene-editing data and retatrutide results are encouraging but remain too preliminary to override pipeline and competitive risks."
The article spotlights early positive data for Verve-102 (51-88% PCSK9 reduction, up to 62% LDL-C drop) and retatrutide Phase 3 weight loss up to 26.1%, plus analyst targets of $1,250-$1,350. These support LLY's cardiometabolic pipeline strength, yet the piece is framed within a promotional push for unrelated AI stocks, and dates reference 2026 events. Phase 1b results involve only 35 participants with variable durability, while retatrutide modeling assumes 70% success and 2027 launch. Missing context includes base-editing safety risks, obesity market competition, and how in vivo gene editing scales commercially versus existing GLP-1 therapies.
The strongest case against a neutral stance is that dose-dependent, durable LDL-C reductions in humans could de-risk the platform faster than expected, justifying premium multiples if retatrutide hits modeled $11B sales by 2034.
"Verve-102's PCSK9 knockdown doesn't proportionally reduce LDL-C, raising questions about mechanism and real-world efficacy before Phase 2 data; retatrutide upside is real but already priced in at current multiples."
Verve-102's Phase 1b data is genuinely impressive on the surface—88% PCSK9 reduction at top dose, 18-month durability—but the LDL-C response is oddly flat: only 62% reduction despite 88% target suppression. This disconnect suggests either target engagement doesn't linearly drive efficacy, or there's compensatory biology we don't yet understand. The retatrutide Phase 3 wins are real, but RBC's $11B 2034 sales forecast assumes zero competition erosion in a crowded GLP-1 market by then. More critically: both programs are years from peak revenue, and LLY's current valuation already prices in obesity dominance. The article's pivot to 'AI stocks offer greater upside' is editorial noise, but it flags real opportunity cost.
If Verve-102's PCSK9 suppression translates to durable cardiovascular outcomes in Phase 2b/3, a one-time genetic edit could disrupt the entire statin and PCSK9 inhibitor market—potentially $50B+ TAM—making current LLY valuation cheap on a 10-year view.
"Lilly is transitioning from a traditional pharmaceutical company to a platform-based biotech powerhouse capable of dominating both the obesity market and the next generation of genetic cardiovascular medicine."
Eli Lilly is effectively building a 'cardiometabolic fortress.' The Verve-102 data, while early-stage, represents a paradigm shift from chronic GLP-1 injections to potentially one-and-done genetic medicine, which would fundamentally disrupt the long-term revenue model for chronic care. When combined with the 26-30% weight loss efficacy of retatrutide, Lilly is positioning itself to capture both the lifestyle and the underlying genetic drivers of cardiovascular disease. However, the market is currently pricing in perfection. With a forward P/E ratio exceeding 60x, any regulatory hiccup in the 2027 retatrutide launch or unforeseen long-term safety signals from gene editing will lead to a violent de-rating of the stock.
The immense cost and clinical complexity of in vivo gene editing may limit Verve-102 to a niche, ultra-high-risk patient population, failing to achieve the mass-market scale required to justify Lilly's current premium valuation.
"Verve-102’s early data are not a reliable foundation for near-term upside given unresolved safety/regulatory risks and lack of clinical outcome proof."
Verve-102 Phase 1b data show intriguing, but very early signals: N=35, dose-responsive PCSK9 reductions (51–88%) and LDL-C drops up to ~62% with durability claimed to 18 months. Yet safety data are absent, delivery/remedy specifics unclear, and in vivo base editing carries significant off-target and immune risk, plus an uncertain regulatory path for a permanent liver edit. Translation from LDL-C reduction to reduced ASCVD events is not demonstrated. The obesity program (retatrutide) also remains early-stage; even with strong signals, long-run safety, cost, and payer dynamics will drive real upside. The stock’s rally could be fragile if these risks materialize or if timelines slip.
The strongest counter: Phase 1b size and scope are too small to infer durable clinical benefit; safety/off-target risks and a murky regulatory path could derail Verve-102 before Phase 2/3 even starts, making upside speculative.
"Verve-102's manufacturing and reimbursement hurdles are understated relative to retatrutide's scalable peptide production."
Gemini assumes Verve-102 scales like retatrutide into a broad cardiometabolic fortress, yet in vivo base editing demands specialized GMP manufacturing of LNPs with lot-to-lot editing consistency that Lilly has never demonstrated at obesity-drug volumes. This bottleneck, plus one-time therapy reimbursement fights with payers, could confine Verve-102 to narrow high-risk segments even if durability holds, capping revenue well below the $50B TAM cited elsewhere and amplifying de-rating risk if timelines slip.
"Manufacturing scale is achievable; the real gate is whether payers value one-time durability over chronic therapy economics."
Grok's manufacturing bottleneck argument is sharp, but it conflates two separate problems. LNP consistency is solvable—Moderna and BioNTech scaled it to billions of doses. The real constraint is payer reimbursement for one-time edits in a $100K+ range competing against $300/month GLP-1s. That's a willingness-to-pay problem, not a GMP problem. If Verve-102 shows durable CV outcomes, payers may accept it; if not, manufacturing capacity becomes irrelevant.
"The permanent nature of in vivo base editing creates a regulatory and safety barrier that prevents it from scaling like transient mRNA therapies."
Claude, your LNP manufacturing comparison is dangerous. Moderna's mRNA degrades; it doesn't permanently alter the genome. The regulatory and safety burden of delivering a CRISPR-based base editor—which carries permanent off-target risk—is orders of magnitude higher than a transient vaccine. Scaling this isn't just a volume issue; it's a massive clinical trial hurdle. If the FDA requires long-term monitoring for oncogenic risk, the 'one-and-done' cost-benefit analysis against GLP-1s collapses entirely, regardless of payer willingness.
"Long-term safety tail risk and payer/regulatory hurdles for permanent genome edits could cap Verve-102's upside even if CV outcomes look durable."
Gemini's one-and-done thesis hinges on favorable CV outcomes and payer acceptance, but permanent liver base editing carries a long-tail safety burden regulators will scrutinize for decades. Even with durable LDL-C/ASCVD signals, long-term oncogenic and off-target risks could trigger post-approval surveillance costs, denial of coverage, and slower uptake than implied. Manufacturing isn't the only bottleneck—the regulatory tail risk and payer risk could erode the multiple from a 50B TAM to a fraction of that.
The panelists agree that Eli Lilly's Verve-102 and retatrutide programs show early promise but face significant hurdles, including manufacturing challenges, regulatory risks, and payer acceptance. The market's high valuation already prices in perfection, making it vulnerable to any setbacks.
Potential paradigm shift from chronic GLP-1 injections to one-and-done genetic medicine
Regulatory tail risk and payer acceptance for one-time edits